Over the past two decades randomized controlled trials of combination treatments for Pulmonary Arterial Hypertension (PAH) have demonstrated improvements of clinical status but only modest reductions in mean pulmonary arterial pressure (mPAP). Recent experiences with upfront combination treatments including parenteral prostacyclins have shown more substantial mPAP reductions, and have provided grounds for reconsiderations of treatment.

Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact / Badagliacca, Roberto; Vizza, Carmine Dario; Lang, Irene; Sadushi-Kolici, Roela; Papa, Silvia; Manzi, Giovanna; Filomena, Domenico; Ogawa, Aiko; Shimokawahara, Hiroto; Matsubara, Hiromi. - In: VASCULAR PHARMACOLOGY. - ISSN 1879-3649. - 146:(2022). [10.1016/j.vph.2022.107099]

Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact

Badagliacca, Roberto
;
Vizza, Carmine Dario;Papa, Silvia;Manzi, Giovanna;Filomena, Domenico;
2022

Abstract

Over the past two decades randomized controlled trials of combination treatments for Pulmonary Arterial Hypertension (PAH) have demonstrated improvements of clinical status but only modest reductions in mean pulmonary arterial pressure (mPAP). Recent experiences with upfront combination treatments including parenteral prostacyclins have shown more substantial mPAP reductions, and have provided grounds for reconsiderations of treatment.
2022
prognosis; pulmonary arterial hypertension; pulmonary pressure; risk assessment
01 Pubblicazione su rivista::01a Articolo in rivista
Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact / Badagliacca, Roberto; Vizza, Carmine Dario; Lang, Irene; Sadushi-Kolici, Roela; Papa, Silvia; Manzi, Giovanna; Filomena, Domenico; Ogawa, Aiko; Shimokawahara, Hiroto; Matsubara, Hiromi. - In: VASCULAR PHARMACOLOGY. - ISSN 1879-3649. - 146:(2022). [10.1016/j.vph.2022.107099]
File allegati a questo prodotto
File Dimensione Formato  
Badagliacca_Pulmonary_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.88 MB
Formato Adobe PDF
2.88 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1655324
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact